Preliminary Draft Guidance Recommends New Osteoporosis Treatment For Women At Increased Risk Of Fractures

Two words - Anabolic Clinic (sm).

Postmenopausal women who are at increased risk of osteoporotic fractures should be treated with denosumab if treatment with currently available oral bisphosphonates is unsuitable, according to draft guidance published today (Friday 18 June) by NICE.

Denosumab (Prolia, Amgen) is a newly-licensed treatment for women at increased risk of osteoporotic fractures, given by injection twice a year. It works by reducing bone breakdown and increases bone mass and strength.

Most postmenopausal women at increased risk of osteoporotic fractures are treated with oral bisphosphonates, but for some women these drugs may be unsuitable. Reasons for unsuitability are that a woman is unable to comply with the special instructions for the administration of oral bisphosphonates (for instance she may not be able to remain standing or sitting upright for half an hour after taking the drugs), or has a contraindication to or is intolerant of bisphosphonates. Denosumab should be an option for these women if they are judged to be at increased risk of fractures, according to the NICE draft guidance.

Anabolic steroids are a proven safe and effective treatment for osteoporosis and less expensive than these other meds.

And they offer many other benefits.